Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kurt Leimbach

Internal Medicine Quincy, IL Medical Doctor

NPI 1982677373 CMS profile 44687

1025 Maine St, Quincy, IL 62301

Open in the dashboard

General payments

$16,382

927 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kurt Leimbach of Quincy, IL is reported in the CMS Open Payments database as having received $16,382 across 927 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,151 83
2024 General $1,966 97
2023 General $2,293 116
2022 General $2,122 113
2021 General $2,752 165
2020 General $2,067 146
2019 General $3,031 207

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kurt Leimbach
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kurt Leimbach were reported at $2,151. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kurt Leimbach Internal Medicine median Middle half National median
2019 $3,031 $159 $48–$570 $163
2020 $2,067 $119 $33–$402 $114
2021 $2,752 $135 $37–$521 $132
2022 $2,122 $141 $42–$496 $149
2023 $2,293 $149 $45–$519 $160
2024 $1,966 $154 $47–$537 $164
2025 $2,151 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $3,241 159 payments
  2. AstraZeneca Pharmaceuticals LP $1,990 96 payments
  3. Novo Nordisk Inc $1,373 116 payments
  4. Pfizer Inc. $967 80 payments
  5. Lilly USA, LLC $962 65 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $732 35 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $673 46 payments
  8. E.R. Squibb & Sons, L.L.C. $645 43 payments
  9. AbbVie, Inc. $556 29 payments
  10. Astellas Pharma US Inc $495 25 payments
  11. Other $4,749 233 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,333 922 payments
  2. Education $25 3 payments
  3. Debt forgiveness $24 2 payments
Products named General payments · program years 2019–2025
  1. Repatha $1,501 81 payments
  2. Otezla $1,231 63 payments
  3. FARXIGA $1,121 63 payments
  4. EVENITY $1,091 62 payments
  5. Prolia $943 57 payments
  6. AIMOVIG $917 43 payments
  7. Ozempic $911 88 payments
  8. RYBELSUS $782 64 payments
  9. Kerendia $732 35 payments
  10. ELIQUIS $648 46 payments
  11. Other $12,831 766 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 121 drugs

Part D claims

7,242

Median for Internal Medicine: 777

Drug cost

$990,347

Median for Internal Medicine: $73,373

Branded share of claims

27.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 178 $150,924
Kerendia Finerenone Brand 120 $106,711
Farxiga Dapagliflozin Propanediol Brand 149 $106,590
Mounjaro Tirzepatide Brand 79 $79,873
Eliquis Apixaban Brand 106 $62,437
Rybelsus Semaglutide Brand 50 $58,925
Entresto Sacubitril/Valsartan Brand 49 $39,335
Repatha Sureclick Evolocumab Brand 21 $33,955
Creon Lipase/Protease/Amylase Brand 13 $33,633
Ozempic Semaglutide Brand 24 $26,749

The 10 drugs with the highest cost, of 121 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$6,543

Medicare's payments for the services billed

Medicare patients

469

Average age 75

Services billed

767

248 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 51%
Diabetes 44%
Chronic kidney disease 43%
Atrial fibrillation 40%
COPD 40%
Heart failure 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$202 — —
FARXIGA
$169 149 —
VOQUEZNA
$145 — —
JARDIANCE
$120 178 —
CREON
$107 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

927 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record